Abstracts Archive - Page 168 of 2607 - ACR Meeting Abstracts

Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Juan Liang¹ and kaiyuan zi², ¹Gempharmatech, Nanjing, Jiangsu, China, ²Gempharmatech, Nanjing, Jiangsu, Jiangsu, China
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…
Abstract Number: 0600 • ACR Convergence 2025
Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Ahlam Almarzooqi¹, Sarah Al Qassimi², Nelly Ziade³, Mohammed Omair⁴, Samar Al emadi⁵, FARIDA ALBALUSHI⁶, Waleed Hafiz⁷, Hiba Khogali⁸, Saadeya Naji⁹, Suzan Attar¹⁰, Khalid Alnaqbi¹¹ and Rajaie Namas¹², ¹Emirates Health Services, Sharjah, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ⁴King Saud university, Riyadh, Saudi Arabia, ⁵Hamad medical corporation, Doha, Qatar, ⁶Royal hospital, Dubia, United Arab Emirates, ⁷Umm Al-Qura university, Makkah, Makkah, Saudi Arabia, ⁸Madinat Zayed Hospital , Al Dhafra hospitals, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁹Salmaniya medical complex, BAHRAIN, Al Asimah, Bahrain, ¹⁰King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ¹¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ¹²Cleveland Clinic Abu Dhabi, Detroit, MI
Background/Purpose: Difficult-to-treat systemic lupus erythematosus (D2T-SLE) presents a major challenge due to disease heterogeneity and a lack of unified classification. While the D2T concept has…
Abstract Number: 0966 • ACR Convergence 2025
Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
kristina clark¹, Xu Shiwen², Xue Li², Voon H. Ong³ and Christopher Denton⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ²University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…
Abstract Number: 0507 • ACR Convergence 2025
Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren’s disease of recent onset versus sicca controls.
Rosa Elena Cervantes¹, Carina Soto-Fajardo², Fabian Carranza³, Gabriela Hernandez-Molina⁴, Narlly Ruíz Quintero⁵, Daniela Rojas Abarca⁶, Ana Mora⁷, Ada Rocío Morales Meza⁶, Carlos Montiel Castañeda⁸, Angela Maldonado Luna⁹, Fabiola Sánchez Zamudio⁶ and Carlos Pineda², ¹National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra"", Mexico City, Distrito Federal, Mexico, ²National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, ³National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion, México, city, Distrito Federal, Mexico, ⁶National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra", Mexico, City, Distrito Federal, Mexico, ⁷National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, Mexico, ⁸National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra", México, city, Distrito Federal, Mexico, ⁹Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, City, Estado de México, Mexico
Background/Purpose: Sjögren's disease (SjD) is a chronic systemic autoimmune disease primarily affecting the exocrine glands. There is an increasing use of salivary gland ultrasound in…
Abstract Number: 0931 • ACR Convergence 2025
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Salvador Campos¹, Sergio Aguilera², Juan Gutiérrez¹, Isabel Castro³, Patricia Carvajal³, Lorena Carvajal¹, Sergio González⁴, Claudio Molina⁵, María-Julieta González⁶ and María-José Barrera⁵, ¹Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ²Clinica Indisa, Santiago, Region Metropolitana, Chile, ³Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, ⁴Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, ⁵Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ⁶ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
Abstract Number: 1003 • ACR Convergence 2025
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Yan Zhang¹, Brittany Ross¹, Aditi Upadhye¹, Diana Galvan¹, Shaun E Grosskurth¹, Yanjie Bao¹, Romina Riener¹, Annabel Wang¹, Aric Frantz¹, Gregor B Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian I Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
Abstract Number: 0898 • ACR Convergence 2025
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Carley Tasker¹, Nicholas Giovannone², Nyanza Rothman², Sofia Caruso², Julia Provino², Laura Johnsen², Johanna Napetschnig², Jamie Orengo¹, Christos Kyratsous², Andre Limnander¹, Katherine Cygnar² and Andrew Baik², ¹Regeneron, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
Abstract Number: 0976 • ACR Convergence 2025
LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Yuan Zhan¹, Colton Sanders², Michael Diaz², Jinmin Miao³, Arminja Kettenbach⁴, Zhong-Yin Zhang⁵, Paul Wolters⁶, Francesco Boin⁷, Stephanie Stanford² and Nunzio Bottini⁸, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³Purdue University, West Lafayette, IN, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, ⁶University of California San Francisco, San Francisco, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The identification of effective and safe anti-fibrotic agents is a critical unmet need in systemic sclerosis (SSc). Although fibrosis in SSc is driven by…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 1012 • ACR Convergence 2025
Racial and Gender Disparities in Gout Clinical Trials
Fizza Zulfiqar¹, Dania Kaur², Meaghan Bethea³, Taylor Spencer⁴, Samhitha Bitla⁵, Abhinav Vyas⁶ and Camelia Arsene⁷, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²North Alabama Medical Center, Muscle Shoals, AL, ³Trinity Health Oakland Hopsital, Pontiac, MI, ⁴Trinity Health Oaklnd Hospital, Pontiac, MI, ⁵Trinity Health Oakland Hospital, Pontiac, MI, ⁶Vanderbilt University, Nashvile, TN, ⁷Trinity Health Oakland Hospital, Pontiac
Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 0990 • ACR Convergence 2025
An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model
laetitia Pouzol, Patrizia Murer, Nicole Egli, Laetitia Petersen, Anais Zurbach, christian Stocker, alexander Rau, andreas Katopodis and christoph huber, Anaveon, Basel, Switzerland
Background/Purpose: PD-1+ T cells play a pivotal role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis. Therapeutic antibodies targeting PD-1 with both depleting and…
Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Fadi Kharouf¹, Pankti Mehta², Qixuan Li², Dafna D. Gladman³, Laura Whitall Garcia⁴ and Zahi Touma⁵, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
Abstract Number: 1013 • ACR Convergence 2025
All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states
Gabriela Accetta Rojas¹, Evan Mulvihill², Salma Siddique¹ and Annemarie Brescia¹, ¹Nemours Children's Hospital of Delaware, Wilmington, DE, ²Nemours/A.I.duPont Hospital for Children, Wilmington, DE
Background/Purpose: Rheumatology is among the pediatric subspecialties with the lowest workforce density in the US1. Initial management of most of the pediatric rheumatologic conditions relies…
Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 0630 • ACR Convergence 2025
Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
Ranjan Gupta, Rudra Prosad Goswami and Anju Mohan, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients’ knowledge, beliefs and perception about their disease. However, there is a lack of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].